Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems.
hepatocellular carcinoma
prognosis prediction
risk scoring
transarterial chemoembolization
tumor burden
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
01
2022
accepted:
28
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Recently, several scoring systems for prognosis prediction based on tumor burden have been promoted for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). This multicenter study aimed to perform the first head-to-head comparison of three scoring systems. We retrospectively enrolled 849 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. The tumor burden score (TBS), the Six-and-Twelve score (SAT), and the Seven-Eleven criteria (SEC) were calculated based on the maximum lesion size and the number of tumor nodes. All scores were compared in univariate and multivariate regression analyses, adjusted for established risk factors. The median overall survival (OS) times were 33.0, 18.3, and 12.8 months for patients with low, medium, and high TBS, respectively (p<0.001). The median OS times were 30.0, 16.9, and 10.2 months for patients with low, medium, and high SAT, respectively (p<0.001). The median OS times were 27.0, 16.7, and 10.5 for patients with low, medium, and high SEC, respectively (p<0.001). In a multivariate analysis, only the SAT remained an independent prognostic factor. The C-Indexes were 0.54 for the TBS, 0.59 for the SAT, and 0.58 for the SEC. In a direct head-to-head comparison, the SAT was superior to the TBS and SEC in survival stratification and predictive ability. Therefore, the SAT can be considered when estimating the tumor burden. However, all three scores showed only moderate predictive power. Therefore, tumor burden should only be one component among many in treatment decision making.
Identifiants
pubmed: 35280804
doi: 10.3389/fonc.2022.850454
pmc: PMC8904349
doi:
Types de publication
Journal Article
Langues
eng
Pagination
850454Informations de copyright
Copyright © 2022 Müller, Hahn, Auer, Fehrenbach, Gebauer, Haubold, Zensen, Kim, Eisenblätter, Diallo, Bettinger, Steinle, Chang, Zopfs, Pinto dos Santos and Kloeckner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
J Gastrointest Cancer. 2021 Dec;52(4):1340-1349
pubmed: 34611834
BMC Cancer. 2015 Jun 10;15:465
pubmed: 26059447
Liver Int. 2016 Jan;36(1):92-9
pubmed: 25950442
J Hepatol. 2019 May;70(5):893-903
pubmed: 30660709
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Vasc Interv Radiol. 2011 Nov;22(11):1545-52
pubmed: 21849247
Oncotarget. 2016 Jul 12;7(28):44705-44718
pubmed: 27244889
Liver Int. 2017 Dec;37(12):1861-1868
pubmed: 28581250
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5
pubmed: 22009576
J Hepatol. 2019 Nov;71(5):1051-1052
pubmed: 31515044
Cardiovasc Intervent Radiol. 2017 Jul;40(7):1017-1025
pubmed: 28197830
Liver Cancer. 2021 Jul 22;10(6):629-640
pubmed: 34950185
World J Hepatol. 2020 Aug 27;12(8):525-532
pubmed: 32952879
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Stat Med. 2011 May 10;30(10):1105-17
pubmed: 21484848
World J Clin Cases. 2021 Jun 26;9(18):4559-4572
pubmed: 34222423
Front Oncol. 2021 Jun 10;11:696183
pubmed: 34178694
J Gastroenterol Hepatol. 2021 Nov;36(11):3196-3203
pubmed: 34159651
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Liver Int. 2019 Feb;39(2):324-331
pubmed: 30318826
Liver Int. 2016 Jan;36(1):100-7
pubmed: 26013186
Liver Int. 2019 Sep;39(9):1704-1712
pubmed: 31319016
Cancers (Basel). 2020 Nov 14;12(11):
pubmed: 33202588
Acta Radiol. 2021 Mar;62(3):313-321
pubmed: 32498543
Eur Radiol. 2021 Jun;31(6):4367-4376
pubmed: 33274405
Br J Surg. 2020 Jun;107(7):854-864
pubmed: 32057105
Liver Int. 2020 Mar;40(3):694-703
pubmed: 31943703
Ann Surg. 2018 Jan;267(1):132-141
pubmed: 27763897
J Gastrointest Surg. 2018 May;22(5):859-871
pubmed: 29352441
Rev Esp Enferm Dig. 2022 Jan;114(1):28-34
pubmed: 33733800
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Clin Transl Gastroenterol. 2021 Feb 18;12(2):e00310
pubmed: 33605612
Circulation. 2015 Jan 13;131(2):211-9
pubmed: 25561516
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52
pubmed: 19908093
Br J Cancer. 2014 Jul 15;111(2):255-64
pubmed: 24937669
J Hepatol. 2014 Dec;61(6):1287-96
pubmed: 25016222
United European Gastroenterol J. 2021 Jun;9(5):590-597
pubmed: 34077613
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536